Icotrokinra Sustains Psoriasis Skin Clearance Through 2 Years
Two-year ICONIC-LEAD data show oral IL-23 receptor antagonist icotrokinra sustained skin clearance in plaque psoriasis, strengthening its case against injectable biologics.
Topic
Il 23
Topic
Il 23
FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis
The FDA has approved icotrokinra, the first oral IL-23 receptor antagonist for psoriasis, giving dermatologists a tablet-based op…
Immunogenetics Is Reshaping Psoriasis Diagnosis and Treatment
A Nature review argues psoriasis immunogenetics — from HLA variants to IL-23/TH17 pathway genetics — is ready to move from discov…